Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBlue Cross Blue Shield KS germline cancer testing …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedblue cross blue shield - kansasPolicy N/A

    Germline genetic testing for hereditary cancer (BRCA1/2, PALB2, and multigene panels)

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs use of germline genetic testing, including next-generation sequencing (NGS) multigene cancer susceptibility panels (limited and expanded), for individuals with personal and/or family histories suggesting inherited cancer syndromes. It applies to providers and members covered by Blue Cross and Blue Shield of Kansas plans.

    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyGermline genetic testing for hereditary cancer (BRCA1/2, PALB2, and multigene panels)
    Policy CodePolicy N/A
    Change TypeCoding update and editorial revisions
    Effective DateFeb 3, 2026
    Last ReviewFeb 3, 2026
    Next Review DateFeb 3, 2026
    Key ActionVerify member benefits with BCBSKS Customer Service and update prior-authorization/coding workflows to reflect removal of deleted codes.
    SourceLink
    POLICY UPDATE CHANGES

    Removed Deleted Codes 0131U, 0132U and 0135U (eff. 01-01-2026)

    Updated Rationale Section

    Updated Coding Section

    Updated References Section

    >99%Concordance NGS vs Sanger
    20+Genes summarized
    ~50%VUS rate (large panels)
    limited/expandedPanel types described
    permittedRepeat testing allowed
    3 codesDeleted codes removed

    Coverage Criteria

    General coverage criteria (excerpt)

    Covered when ALL of the following are met

    Clinical indication: Personal and/or family history suggesting an inherited cancer syndrome

    Documented personal and/or family history required (e.g., early-onset cancer, multiple primary tumors, first-degree relative with relevant cancer).

    Test type and intent: Germline testing intended for hereditary cancer risk assessment — single-gene testing, syndrome-focused limited multigene panels, or tailored multigene panels as appropriate to the phenotype

    Panel composition should match the clinical indication; somatic/therapeutic tumor testing is a different intended use and is not covered under these germline criteria.

    Medically Necessary — Multigene Panel Testing

    Covered when ONE of the following is met:

    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyGermline genetic testing for hereditary cancer (BRCA1/2, PALB2, and multigene panels)
    Policy CodePolicy N/A
    Change TypeCoding update and editorial revisions
    Effective DateFeb 3, 2026
    Last ReviewFeb 3, 2026
    Next Review DateFeb 3, 2026
    Key ActionVerify member benefits with BCBSKS Customer Service and update prior-authorization/coding workflows to reflect removal of deleted codes.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsEligibility RequirementsProvider Actions and Documentation RequirementsCoding and BillingDefinitions and BackgroundNot Covered / ExperimentalRevision History
    A.1: Coverage criteria of another relevant policy are met, or in the absence of another policy the family history is suggestive of a specific inherited cancer syndrome

    See related syndrome-specific policies and Policy Guidelines (e.g., NCCN criteria).

    A.2: Individual previously had limited or incomplete genetic testing (e.g., single-gene testing without deletion/duplication analysis or a small panel), tested negative, and personal/family history remains strongly suggestive of inherited susceptibility; multigene testing is pursued when there are substantial technological improvements compared with prior testing

    Coverage contingent on justification that prior testing was incomplete and that expanded testing could detect variants missed by earlier methods.

    A.3: A pathogenic (disease-associated) variant has been identified in the family but does not fully explain the proband's signs or symptoms

    Multigene testing may be indicated to search for an additional explanatory variant.

    Not Medically Necessary / Experimental

    B: All other uses of multigene panels for genetic cancer susceptibility testing

    Considered experimental/investigational when not meeting A.1–A.3 or policy-specific criteria.

    Coverage stance for multigene panels

    Policy distinguishes between when multigene panels are considered medically necessary vs experimental/investigational

    Medically necessary limited panels: Limited or tailored multigene panels that include only genes pertinent to the specific cancer indication (i.e., the more strongly recommended genes from Table 1, with or without less strongly recommended genes) may be considered medically necessary when the individual meets established criteria (eg, NCCN/ASCO guidance or related policy criteria).

    Panel should be phenotype-directed and include only genes supported by the individual's personal/family history.

    Experimental/Investigational: Expanded or unfocused multigene panels that include genes not justified by the individual's phenotype or panels that do not meet policy-specific clinical criteria.

    These uses are considered experimental/investigational due to limited clinical validity/utility and increased VUS rates.

    Panel selection, retesting, and family testing strategy

    Selection and retesting guidance

    Panel selection: Select a panel based on age at presentation, family cancer phenotype(s), and detailed personal and family history (including first- and second-degree relatives and ethnicity). Include the more strongly recommended genes for the specific cancer indication; include less strongly recommended genes only when clinically justified.

    When more than one gene is relevant, multigene testing is appropriate per ASCO/NCCN guidance.

    Retesting: Repeat germline panel testing is generally not needed during an individual's lifetime but is supported when there have been substantial technological advances or when the laboratory test has been updated since prior testing.

    Document rationale for retesting (eg, earlier testing lacked deletion/duplication analysis or used less comprehensive methods).

    Testing at-risk relatives: 'At-risk relatives' primarily refers to first-degree relatives; familial assessment should consider 1st-, 2nd-, and 3rd-degree relatives as needed.

    Define relatives per policy (1st-, 2nd-, 3rd-degree) when determining testing strategy.

    Targeted variant testing: When possible, perform initial testing in an affected family member so that unaffected relatives may undergo targeted testing for the known familial pathogenic variant rather than full gene sequencing.

    Testing unaffected relatives without first testing an affected relative is discouraged because most results will be negative/uninformative.

    This policy differentiates germline risk‑assessment panels from therapeutic somatic tumor testing. Germline multigene panels are intended to assess inherited cancer risk in asymptomatic or at‑risk individuals based on personal and/or family history, whereas somatic tumor testing is performed on tumor tissue to identify somatic variants that may direct targeted therapy. Coverage guidance in this policy applies to germline testing for hereditary cancer susceptibility and does not apply to somatic tumor profiling done for therapeutic decision‑making.

    No explicit coverage exclusions are listed in the excerpted gene summaries. The policy notes that state and federal mandates and member contract provisions take precedence and should be verified prior to ordering, but does not specify additional categorical exclusions in this portion of the document.

    Multigene panel uses that do not meet the medical necessity criteria (policy A.1–A.3) are classified as experimental/investigational and are not supported under this policy. The policy specifies that coverage for panels is contingent on meeting one of the listed coverage criteria (eg, meeting related policy criteria, prior limited testing with persistent suspicion, or family pathogenic variant not fully explanatory).

    The policy highlights that large, comprehensive panels are associated with higher rates of variants of uncertain significance (VUS) and more incidental or unexpected findings not directly related to the presenting cancer. Reported VUS rates rise with panel size and have been observed to approach ~50% for large gene panels, which increases the likelihood of results that may not change clinical management.

    Expanded panels that include genes with unknown or variable cancer risk have uncertain clinical validity. Because management recommendations for low‑to‑moderate penetrance genes are not standardized, the clinical utility for many genes on expanded panels is uncertain and may lead to potential harm or unclear management pathways.

    The policy states that all other uses of multigene panels for genetic cancer susceptibility testing that do not meet specified criteria are considered experimental/investigational. Expanded or unfocused panels beyond the recommended, indication‑specific gene sets fall into this category.

    Within the excerpted portions of the document there are no additional explicit exclusions listed beyond those described under the policy’s experimental/investigational statements and the guidance to verify member contract provisions and state/federal mandates.

    The gene‑specific summaries included in this excerpt do not contain statements declaring particular genes or tests as not medically necessary. Instead, the policy uses group‑level criteria to determine whether panel testing is supported.

    Panels that do not meet the policy’s stated criteria (for example, those ordered without a qualifying personal/family history or not meeting related policy criteria) are not supported by this policy and are considered experimental/investigational.

    For many genes included on expanded panels, the chain of evidence linking analytic validity to clinical validity and then to clinical utility is incomplete. When clinical validity for specific genes is not established, the downstream evidence for clinical utility is lacking, limiting the ability to justify their inclusion for routine clinical decision‑making.

    The policy reiterates that general genetic cancer susceptibility panel testing is considered experimental/investigational except in circumstances covered by the policy criteria or when coverage is governed by other, syndrome‑specific policies. Limited, indication‑focused panels that meet coverage criteria may be considered medically necessary.

    The policy discourages ordering sequencing in unaffected relatives before testing an affected family member when available. It recommends that, when possible, initial testing be performed in an affected family member so unaffected relatives can undergo targeted variant testing for a known familial pathogenic variant, reducing uninformative negative results.

    Covered Indications

    Individuals with personal and/or family history suggesting an inherited cancer syndrome for whom germline risk assessment is indicated.

    Population: Individuals with personal and/or family history suggesting an inherited cancer syndrome for whom germline risk assessment is indicated

    Includes individuals considered for BRCA1/2, PALB2, and other hereditary cancer gene testing via limited or tailored multigene panels.

    Hereditary breast, ovarian, pancreatic, gastrointestinal, endocrine, melanoma, renal, and other familial cancers associated with listed genes.

    Hereditary cancer examples: Hereditary breast, ovarian, pancreatic, gastrointestinal, endocrine, melanoma, renal, and other familial cancers associated with listed genes (examples include PALB2 for breast/pancreatic cancer; STK11 associated with Peutz-Jeghers and high cancer risk; TP53 associated with Li-Fraumeni syndrome).

    Gene-specific risks and inheritance patterns inform panel selection and management.

    Hereditary cancer predisposition across multiple cancer types where Table 1 genes are relevant; panels should include strongly recommended genes

    Pan-cancer relevance: Hereditary cancer predisposition across multiple cancer types where Table 1 genes are relevant (eg, breast, ovarian, colorectal, endometrial, gastric, pancreatic, prostate, renal, melanoma, sarcoma); panels should at minimum include the more strongly recommended genes for the specific cancer indication and may include less strongly recommended genes when clinically justified.

    Refer to Table 1 for cancer-specific gene recommendations when assembling a limited/tailored panel.

    Individuals where testing would provide predictive information that could change management or surveillance.

    Clinical utility requirement: Individuals whose testing would provide predictive information that could change management or surveillance (ie, marker–disease association established and identifying a variant would alter clinical care).

    Testing should be ordered only when results would inform management, surveillance, or therapeutic decisions.

    Patients with colorectal cancer meeting criteria (eg mismatch repair deficiency, early-onset CRC, multiple primaries, relevant family history) or meeting Lynch/hereditary breast/ovarian criteria.

    CRC-specific criteria: Patients with colorectal cancer meeting at least one clinical criterion (mismatch repair deficiency not explained by MLH1 hypermethylation, CRC diagnosis <50 years, multiple primary tumors [CRC or endometrial cancer], or a first-degree relative with CRC or endometrial cancer) — these patients should undergo appropriate germline multigene testing guided by tumor testing results.

    Use tumor MMR testing to triage panel selection; panels used varied from 25–66 genes in cited studies.

    Alternate pathway: Patients meeting hereditary breast/ovarian cancer or established Lynch syndrome testing criteria per relevant guidelines (eg, NCCN) should be evaluated for genetic testing accordingly.

    Follow syndrome-specific policies and guidelines for testing eligibility and panel composition.

    Individuals whose history suggests inherited susceptibility for listed cancers where a tailored limited multigene panel is indicated per NCCN/ASCO guidance.

    Tailored limited-panel indication: Individuals whose personal and/or family history suggests inherited susceptibility for breast, ovarian, pancreatic, prostate, colorectal, endometrial, or gastric cancer, where a tailored limited multigene panel is indicated per NCCN/ASCO guidance

    Coverage for limited/tailored panels is contingent on meeting policy-specific criteria and documentation of family history per guideline recommendations (include first- and second-degree relatives and ethnicity).

    High-risk syndromes: Hereditary breast, ovarian, and other high-risk cancer syndromes where personal and/or family history suggests increased genetic risk; panel selection should consider age at presentation and family cancer phenotypes.

    When more than one gene is relevant, offer multigene testing; broaden panel only when benefits outweigh risks of uncertain findings.

    Hereditary breast, ovarian, and other high-risk cancer syndromes where personal/family history suggests increased genetic risk — panel selection considerations

    Breast/ovarian/high-risk considerations: Hereditary breast, ovarian, and other high-risk cancer syndromes: personal and/or family history suggesting increased genetic risk should prompt consideration of a phenotype-directed panel that includes the more strongly recommended genes (eg, BRCA1, BRCA2, PALB2, TP53, CDH1, PTEN, STK11) and additional genes when clinically indicated.

    Document age at diagnosis, tumor phenotype, and detailed family history to guide panel composition.

    Eligibility Requirements

    ELIGIBILITY REQUIREMENTS: The excerpt contains no top‑level eligibility nodes. Coverage is tied to the general statement that testing applies to individuals with a documented personal and/or family history suggestive of an inherited cancer syndrome; specific numeric or categorical eligibility thresholds are not provided in this section.

    ELIGIBILITY REQUIREMENTS: No discrete top‑level eligibility nodes are present in this excerpt. The policy’s applicability rests on documented personal and family history consistent with inherited cancer risk rather than prespecified checklist items in the provided text.

    ELIGIBILITY REQUIREMENTS: The relevant population for germline testing comprises individuals with a documented personal and/or family history suggestive of an inherited cancer syndrome (eg, early‑onset cancer, multiple primaries, or a family pattern consistent with known syndromes). Testing consideration is driven by whether results would provide predictive information that could change management or surveillance.

    ELIGIBILITY REQUIREMENTS: The policy refers to established guideline criteria (eg, NCCN) for genetic risk evaluation; documented family history including first‑ and second‑degree relatives and ethnicity should be recorded to guide panel selection. Individuals meeting those guideline criteria are the intended population for testing.

    ELIGIBILITY REQUIREMENTS: The policy emphasizes that testing is intended for people whose personal and/or family histories suggest inherited susceptibility. The excerpt does not enumerate numeric cutoffs but indicates that eligibility hinges on whether testing would inform management.

    ELIGIBILITY REQUIREMENTS: Individuals with early‑onset cancers, multiple primary tumors, or first‑degree relatives with relevant cancers are examples of the populations for whom germline multigene testing may be appropriate when findings would alter clinical care.

    ELIGIBILITY REQUIREMENTS: No additional top‑level nodes are provided in this excerpt; the policy’s eligibility framework is based on documented clinical and family history suggestive of an inherited cancer syndrome.

    ELIGIBILITY REQUIREMENTS: No discrete eligibility nodes are specified here; determination of appropriateness should be grounded in the documented history and guideline concordant risk assessment.

    ELIGIBILITY REQUIREMENTS: This excerpt contains no additional structured eligibility criteria beyond the general requirement for a personal and/or family history suggestive of an inherited cancer syndrome.

    ELIGIBILITY REQUIREMENTS: The document does not list further top‑level eligibility nodes in the provided text; clinical judgment aligned with guideline criteria is implied for determining eligibility.

    ELIGIBILITY REQUIREMENTS: The evidence base and analyses referenced in the policy often compare patients with and without prior syndrome‑based or BRCA1/BRCA2 testing; prior targeted testing history may influence subsequent panel selection and coverage determinations in specific cases.

    ELIGIBILITY REQUIREMENTS: Several studies and programmatic analyses referenced in the policy separate cohorts based on prior targeted testing (eg, prior BRCA testing), indicating that prior testing history is a relevant consideration when assessing the need for expanded panel testing.

    ELIGIBILITY REQUIREMENTS: No additional top‑level eligibility nodes are present in this excerpt; eligibility decisions should be supported by documented personal/family history and applicable guideline criteria.

    ELIGIBILITY REQUIREMENTS: The excerpted text does not provide further enumerated eligibility criteria beyond those already described; clinicians should reference the full policy and related syndrome‑specific policies for detailed thresholds.

    Provider Actions and Documentation Requirements

    Prior Authorization

    Verify benefits before ordering

    Verify member benefits with Blue Cross and Blue Shield of Kansas Customer Service prior to ordering genetic testing and consider that state or federal mandates and the member's contract language may supersede this policy.

    • Contact BCBSKS Customer Service to confirm coverage and any plan-specific provisions before testing.
    Prior Authorization

    Prior authorization

    No general prior authorization requirements are specified in the excerpt for individual gene summaries; check plan-specific prior authorization rules if applicable.

    Prior Authorization

    Prior authorization for multigene panels

    Prior authorization is required for multigene panel testing to demonstrate that one of the policy's medical necessity criteria is met and to define whether the panel will be limited or expanded.

    • Authorization should document which medical necessity criterion (A.1–A.3) applies and the genes/variants to be included (limited vs expanded panel).
    Prior Authorization

    Confirm genetic counseling and verify benefits

    Confirm and document whether genetic counseling was performed and verify member contract benefits prior to testing; code-level prior authorization instructions are not provided in this excerpt.

    • Document that counseling was provided by an individual with experience in genetic medicine.
    • Verify member contract benefits at time of service.
    Documentation Required

    Clinical justification and panel selection

    Select multigene panels based on the patient's personal and family history; offer multigene panels when more than one gene is relevant and ensure the minimal panel includes the more strongly recommended genes for the specific cancer.

    • Document clinical indication and how panel composition aligns with the patient's history.
    • Prefer limited/tailored panels that include genes pertinent to the specific cancer indication (Table 1).
    Billing Rule

    Code applicability — codes are informational only

    Codes listed in the coding section are provided for informational purposes; inclusion or exclusion of a code does not imply coverage — the service is covered only when performed according to the policy criteria.

    • Refer to the member's contract to determine coverage; codes are medically necessary only if the procedure is performed according to the Policy section.
    Billing Rule

    Coding update — deleted codes removed

    Removed/deleted CPT/HCPCS codes (0131U, 0132U, 0135U) were removed effective 01-01-2026; update prior-authorization and coding workflows to reflect these deletions.

    • Ensure prior-authorization and billing systems do not use deleted codes after 01-01-2026.
    Step Therapy

    Consider focused testing alternatives

    Consider focused alternatives (single-gene or limited-panel testing) as comparator approaches when clinically appropriate; the policy does not mandate prior single-gene testing but suggests considering focused testing versus broad panels.

    • Document rationale when choosing panel testing over targeted single-gene testing.
    Step Therapy

    Step therapy — none specified

    No step therapy requirements (sequential therapy mandates) are described in this excerpt.

    Step Therapy

    Targeted family variant testing preferred

    When a pathogenic familial variant has been identified in an affected relative, perform targeted variant testing in unaffected relatives for that specific familial pathogenic variant rather than sequencing the entire gene.

    • Document the familial pathogenic variant and that targeted testing is being performed in the unaffected relative.
    Documentation Required

    Document rationale for broad/comprehensive panels

    If ordering broad or comprehensive panels as first-tier testing instead of syndrome-based or limited panels, document the clinical rationale given uncertainty about first-line panel testing and potential harms from uncertain results.

    • State why broader panel is expected to provide clear benefits that outweigh increased VUS rates and uncertain clinical validity for some genes.
    Documentation Required

    Syndrome‑based testing consideration

    When syndrome-based (single-gene or targeted) testing would have identified the majority of actionable variants, consider that approach and document why panel testing is nevertheless chosen if ordering a broad panel first-line.

    • Reference evidence or guideline recommendations that syndrome-based testing may be sufficient in many cases.
    Documentation Required

    Document clinical indication and testing intent

    Verify and document the clinical indication: record personal and/or family history suggestive of an inherited cancer syndrome and the intended use of testing (risk assessment versus therapeutic tumor testing).

    • Include the intended use of testing in the record (risk assessment vs therapeutic).
    Documentation Required

    Document family history and pedigree

    Document detailed personal and family history including cancers in first- and second-degree relatives and the patient's ethnicity to support panel selection and justify included genes.

    • Record first- and second-degree relatives' cancer types and ages at diagnosis.
    • Record patient ethnicity as part of family-history documentation.
    Documentation Required

    Document affected-relative testing before unaffected relatives

    If testing unaffected relatives, document that an affected family member was tested first when possible and provide the familial pathogenic variant when available to enable targeted testing.

    • Attach reports showing the affected relative's positive result, or document attempts to test an affected relative.
    • If a familial pathogenic variant is known, list the exact variant.
    Documentation Required

    Document prior testing and clinical history

    Record prior clinical history and prior genetic testing (for example prior BRCA1/BRCA2 testing or syndrome‑based testing) to support selection of a multigene panel or the need for retesting.

    • Document prior testing methods and whether deletion/duplication analysis was included.
    • If prior testing was limited or negative but technology has advanced, note that rationale for multigene retesting.
    Documentation Required

    Family history elements to include

    Include in the documented family history cancers in first- and second-degree relatives and the patient's ethnicity; this information should guide which genes are included on a limited or tailored panel.

    Step Therapy

    Test affected family member first when possible

    Order initial testing in an affected family member when possible; testing an affected relative first enables subsequent targeted variant testing in unaffected relatives if a pathogenic variant is identified.

    • If an affected relative cannot be tested, document reasons and discuss implications for interpretation.
    • When a pathogenic variant is found in the proband, document the variant for targeted testing in relatives.
    Documentation Required

    Affected‑relative‑first then targeted testing

    Recommendation: perform affected-relative‑first testing and then targeted variant testing in unaffected relatives when a pathogenic variant is identified; testing unaffected family members without first testing an affected relative is discouraged because most results will be negative and uninformative.

    Note
    Note
    Denial Risk

    Benefit verification required

    Verify coverage determination considering state and federal mandates and member contract language; failure to verify benefits may lead to denial of coverage.

    • Check plan mandates, exclusions, and prior-authorization requirements before ordering.
    Denial Risk

    Noncovered when criteria not met — risk of denial

    Multigene panel testing that does not meet the policy's medical necessity criteria (A.1–A.3) is considered experimental/investigational and may be denied as not covered.

    • Ensure documentation demonstrates which criterion supports medical necessity before submitting for authorization or billing.
    Denial Risk

    Document genetic counseling to reduce denial risk

    Lack of documented genetic counseling by an experienced genetics professional may increase the risk of inappropriate testing and potential noncoverage; document counseling when performed.

    • Record the counseling provider's qualifications and notes from pre‑ and/or post‑test counseling.
    Denial Risk

    Risk of noncoverage for panels including genes with uncertain validity

    Tests that include genes of unknown or variable cancer risk have uncertain clinical validity and may lead to high VUS rates and potential noncoverage; ordering such expanded panels should be justified and documented.

    • Explain clinical rationale for including genes with uncertain risk and how results would alter management.
    • Be aware that large panels increase the chance of VUS and uncertain clinical utility.
    Billing Rule

    Coding inclusion/exclusion does not guarantee coverage

    Inclusion or exclusion of a procedure or diagnosis code in the policy does not by itself imply coverage or reimbursement; codes are medically necessary only when the service is performed according to the Policy section and the member's contract.

    Denial Risk

    Avoid testing unaffected relatives before proband is tested

    Testing unaffected family members without first testing an affected family member when one is available may produce negative or uninformative results and is discouraged; targeted testing of a known familial pathogenic variant is recommended when available.

    • When unaffected relatives are tested without an affected relative result, document counseling about the likelihood of uninformative results.
    Note
    Note
    Note
    Note

    Coding and Billing

    Covered CPT Codes (informational list)CPT
    81432Hereditary breast cancer-related disorders, genomic sequence analysis panel, 5 or more genes
    81435Hereditary colon cancer-related disorders, genomic sequence analysis panel, 5 or more genes
    81437Hereditary neuroendocrine tumor-related disorders, genomic sequence analysis panel, 5 or more genes
    81445Solid organ neoplasm, genomic sequence analysis panel 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements
    81450Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes
    81455Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, interrogation for sequence variants and copy number variants or rearrangements
    81479Unlisted molecular pathology procedure
    Proprietary / U codes (informational list)CPT
    0048UOncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including MSI
    0049UNPM1 gene analysis, quantitative
    0101UHereditary colon cancer disorders; genomic sequence analysis panel utilizing combination of NGS, Sanger, MLPA and array CGH (15 genes + EPCAM and GREM1)
    0102UHereditary breast cancer-related disorders; genomic sequence analysis panel utilizing NGS, Sanger, MLPA, array CGH, with mRNA analytics (17 genes)
    0103UHereditary ovarian cancer; genomic sequence analysis panel utilizing NGS, Sanger, MLPA, array CGH, with mRNA analytics (24 genes)
    0129UHereditary breast cancer - related disorders, genomic sequence analysis and deletion/duplication panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53)
    0130UHereditary colon cancer disorders, targeted mRNA sequence analysis panel
    0133UHereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes)
    0134UHereditary pan cancer, targeted mRNA sequence analysis panel (18 genes)
    0136UATM mRNA sequence analysis
    1–10 of 13
    1/2
    Removed/Deleted CodesHCPCSNot Covered
    0131UDeleted code (removed eff. 01-01-2026)
    0132UDeleted code (removed eff. 01-01-2026)
    0135UDeleted code (removed eff. 01-01-2026)
    Billing Rule

    Code applicability — informational only

    Codes listed in the Coding section are for informational purposes; coverage applies only when testing is performed according to the Policy criteria.

    Billing Rule

    Coding update — removed deleted codes (01-01-2026)

    Deleted HCPCS codes 0131U, 0132U, and 0135U were removed effective 01-01-2026; update prior-authorization and coding workflows to remove these codes.

    Definitions and Background

    BACKGROUND: Next‑generation sequencing (NGS) enables simultaneous evaluation of multiple genes and is commonly used for hereditary cancer risk assessment. While NGS increases testing efficiency and gene coverage, it also yields a higher number of variants of uncertain significance compared with direct sequencing and may identify findings that do not change management.

    limited vs expanded multigene panels
    Limited multigene panelAssay that includes only the variants/genes pertinent to the specific cancer indication (the more strongly recommended genes for that cancer, with or without less strongly recommended genes).
    Expanded multigene panelAssay that includes variants or genes not relevant to the specific cancer indication or not listed in Table 1; may include broad, pan-cancer gene sets beyond recommended genes for the phenotype.
    Purpose distinctionLimited panels are phenotype‑directed for clinical actionability; expanded panels test many genes and increase likelihood of VUS and findings of uncertain relevance.
    Next-generation sequencing (NGS) definition
    DefinitionNext‑generation sequencing (NGS) refers to massively parallel sequencing methods that allow simultaneous analysis of large stretches of DNA and multiple genes (panel testing).
    Common useWidely used by commercial and academic laboratories for hereditary cancer multigene panels.
    Relative to SangerNGS enables greater throughput and efficiency compared with sequential single‑gene testing, though panel testing may yield more variants of uncertain significance.
    Autosomal recessive vs dominant examples
    Autosomal recessive exampleMUTYH — germline variants associated with autosomal recessive hereditary polyposis; reported in a proportion of APC‑negative polyposis cases.
    Autosomal dominant examplesPALB2, STK11, TP53 — genes typically associated with autosomal dominant inheritance where heterozygotes have increased cancer risk (eg, PALB2: breast/pancreatic; STK11: Peutz‑Jeghers; TP53: Li‑Fraumeni).
    Clinical implicationInheritance pattern guides family testing strategy (eg, MUTYH biallelic disease vs dominant single‑variant familial testing).
    Genetic panel definition — simultaneous evaluation of multiple genes
    DefinitionGenetic panel — a test that simultaneously evaluates multiple genes (eg, via NGS, massive parallel sequencing, or chromosomal microarray), as opposed to sequential single‑gene testing; excludes gene expression profiling.
    Methods includedIncludes panels performed by NGS, massive parallel sequencing, and chromosomal microarray analysis.
    ExclusionDoes not include gene expression profiling panels that do not directly evaluate genetic variants.
    Variant classification — ACMG-AMP terminology and HGVS references
    ACMG‑AMP categoriesUses ACMG‑AMP terminology: Pathogenic, Likely pathogenic, Variant of uncertain significance (VUS), Likely benign, Benign.
    Nomenclature standardHuman Genome Variation Society (HGVS) nomenclature is used to report variants; terminology updated to refer to 'variant' rather than 'mutation'.
    Reporting contextTables PG1 and PG2 outline updated nomenclature and ACMG‑AMP variant classification definitions for reporting findings in DNA.
    Degree relatives — definitions
    First‑degree relativesParents, siblings, and children.
    Second‑degree relativesGrandparents, aunts/uncles, nieces/nephews, grandchildren, and half‑siblings.
    Third‑degree relativesGreat‑grandparents, great‑aunts/uncles, great‑grandchildren, and first cousins.
    Variant nomenclature — updated terminology (variant replaces mutation)
    Terminology update'Variant' replaces the older term 'mutation' in updated nomenclature; 'disease‑associated variant' corresponds to the former 'mutation'.
    Familial variant'Familial variant' refers to a disease‑associated variant identified in a proband for targeted testing in first‑degree relatives.
    Reporting guidanceNomenclature table (PG1) defines updated terms to be used in variant reporting.
    ACMG-AMP variant classification categories
    Five standard categoriesPathogenic; Likely pathogenic; Variant of uncertain significance (VUS); Likely benign; Benign.
    SourceClassification per ACMG‑AMP Standards and Guidelines (Table PG2).
    Clinical useThese categories guide interpretation and clinical decision‑making; pathogenic/likely pathogenic findings may inform management while VUS generally does not.
    Clinically useful definition (clinical utility)
    DefinitionClinically useful (clinical utility) — a test is clinically useful if its results inform management decisions that improve net health outcomes (eg, enable correct or more effective therapy, avoid unnecessary interventions).
    Evaluation criteriaAssess whether test results change management, whether changes improve outcomes, and the impact of ancillary information from panels (positive or negative).
    Utility limitationsVariants with intermediate or low penetrance often have limited clinical utility due to unclear management guidelines and potential for harm.
    VUS definition and implications
    Definition of VUSVariant of uncertain significance (VUS) — a DNA change whose association with disease risk is unclear; effects on disease are uncertain per ACMG‑AMP definitions.
    ImplicationsVUS findings generally should not drive changes in clinical management and can increase psychological stress and lead to unnecessary interventions.
    Panel size relationshipVUS rates increase with panel size; large panels report VUS rates approaching ~50%.
    Tailored multi-gene panel definition
    DefinitionTailored multi‑gene panel — a disease‑focused panel of clinically actionable cancer susceptibility genes specific to the phenotype (NCCN 'tailored' panel), contrasted with large panels of uncertain relevance.
    RecommendationTailored panels are phenotype‑directed and generally include genes most likely to affect management for the individual or family.
    BenefitIncreases yield of actionable pathogenic/likely pathogenic findings and reduces incidental/uncertain findings compared with broad panels.
    limited multigene panel definition
    DefinitionLimited multigene panel — assay including only variants/genes pertinent to the specific cancer indication (the minimal panel should include the more strongly recommended genes from Table 1).
    ContextAppropriate when family history or phenotype points to a specific inherited cancer syndrome; may include less strongly recommended genes as warranted.
    Coverage stanceLimited/tailored panels that match clinical indication may be considered medically necessary when coverage criteria are met.
    expanded multigene panel definition
    DefinitionExpanded multigene panel — panels that include genes or variants not in Table 1 or genes not recommended for the specific cancer type; may include broad pan‑cancer gene sets.
    Evidence concernsExpanded panels include genes with unknown or variable cancer risk; clinical validity and utility are often uncertain and VUS rates are higher.
    Policy stanceExpanded/unfocused panels without justification are considered experimental/investigational and not supported when criteria are not met.
    At-risk relatives — primarily refers to first-degree relatives
    Primary meaning'At‑risk relatives' primarily refers to first‑degree relatives due to high lifetime cancer risk in most genetic syndromes.
    Use of judgmentIn small pedigrees or special circumstances, inclusion of more distant relatives may be necessary; familial assessment uses 1st‑, 2nd‑, and 3rd‑degree definitions.
    Testing priorityTesting strategies typically prioritize affected first‑degree relatives for initial variant identification before testing unaffected relatives.
    Targeted variant testing — definition
    DefinitionTargeted variant testing — testing an unaffected family member specifically for the pathogenic variant identified in an affected family member, rather than sequencing the entire gene.
    RationalePreferred because testing unaffected relatives without a known familial variant is often negative and uninformative; targeted testing avoids unnecessary broad sequencing.
    Recommended sequenceWhen possible, perform initial testing in an affected family member so subsequent testing in relatives can be targeted to identified pathogenic variants.

    Not Covered / Experimental

    NOT COVERED: The policy cautions that broad or expanded panels can produce high rates of VUS and incidental findings that may not alter clinical management. When panels include genes without established clinical validity, results may not be actionable and therefore are not supported by the policy unless coverage criteria are met.

    NOT COVERED: There are no specific named tests or indications listed as definitively not covered in the excerpted material. Coverage determinations depend on whether the ordered testing meets the policy criteria and member contract provisions.

    NOT COVERED: The policy does not support expanded panels that are not justified by the individual’s personal and/or family history or that extend beyond the Table 1 recommended genes for the indicated cancer type without a clear potential benefit. Providers should document rationale when ordering broader panels.

    NOT COVERED: Genes included on expanded panels that have unknown or variable cancer risk and for which clinical validity and utility have not been established are considered not covered in routine practice because they lack demonstrated clinical utility and may generate ambiguous results.

    NOT COVERED: The policy considers expanded multigene panels and other uses of multigene panel testing that do not meet the policy’s specific criteria to be experimental/investigational and therefore not covered.

    NOT COVERED: Within the provided excerpt there are no additional explicit test types or specific clinical indications declared as not covered; determinations are driven by the policy criteria and member contract language.

    Revision History

    2026-02-03Policy effective / reviewLatest

    Policy status updated with current effective and last review date of 2026-02-03 (policy modified).

    2026-01-01Coding update - deleted codes removed

    Deleted HCPCS/CPT proprietary codes 0131U, 0132U and 0135U were removed effective 01-01-2026 and the coding section was updated to reflect their removal.